CSPC Pharma announced its mid-term report for 2024, showing a growth of 1.3% and 1.7% in revenue and attributable net profit to shareholders, respectively. During the period, the company declared an interim dividend of 16 Hong Kong cents per share, representing a 14.3% increase compared to the same period last year. In addition, the company completed a share repurchase of 0.387 billion Hong Kong dollars in the first half of the year and plans to repurchase up to 1 billion Hong Kong dollars worth of shares. Research and development investment increased by 10.3%, reflecting the company's continued investment in innovative drugs. The company repurchased its shares on the Stock Exchange of Hong Kong in April and June 2024 and subsequently canceled them in the following months. The board of directors believes that this move will help enhance shareholder value.

CSPC Pharma announced its mid-term report for 2024, showing a growth of 1.3% and 1.7% in revenue and attributable net profit to shareholders, respectively. During the period, the company declared an interim dividend of 16 Hong Kong cents per share, representing a 14.3% increase compared to the same period last year. In addition, the company completed a share repurchase of 0.387 billion Hong Kong dollars in the first half of the year and plans to repurchase up to 1 billion Hong Kong dollars worth of shares. Research and development investment increased by 10.3%, reflecting the company's continued investment in innovative drugs. The company repurchased its shares on the Stock Exchange of Hong Kong in April and June 2024 and subsequently canceled them in the following months. The board of directors believes that this move will help enhance shareholder value.